Semaglutide (910463-68-2) video
Semaglutide (910463-68-2) Description
Semaglutide is a GLP-1 Receptor Agonist. The mechanism of action of semaglutide is as a Glucagon-like Peptide-1 (GLP-1) Agonist. The chemical classification of semaglutide is Glucagon-Like Peptide 1.
Semaglutide is a once-daily glucagon-like peptide-1 analog that differs to others by the presence of an acyl group with a steric diacid at Lys26 and a large synthetic spacer and modified by the presence of a α-aminobutyric acid in position 8 which gives stability against the dipeptidylpeptidase-4.[A31421] The stability of semaglutide by the acylation permits a high-affinity albumin binding and gives it a long plasma half-life which allows the once-daily dosage. It was developed by the Danish pharmaceutical company Novo Nordisk and FDA approved on December 5, 2017.
Semaglutide (910463-68-2) Specifications
|Chemical Name||Ozempic; UNII-53AXN4NNHX; NN9535; 53AXN4NNHX;|
|Molecular Weight||4113.641 g/mol|
|Biological Half-Life||One week|
|Solubility||Soluble in aqueous solution (5% AcOH) (1mg/ml).|
|Storage Temperature||Stable for at least 1 year after receipt when stored at -20°C.|
|Application||Antidiabetics, Glucagon-like Peptide-1 Agonists|